PE20170893A1 - N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostericos negativos de nr2b - Google Patents

N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostericos negativos de nr2b

Info

Publication number
PE20170893A1
PE20170893A1 PE2017000506A PE2017000506A PE20170893A1 PE 20170893 A1 PE20170893 A1 PE 20170893A1 PE 2017000506 A PE2017000506 A PE 2017000506A PE 2017000506 A PE2017000506 A PE 2017000506A PE 20170893 A1 PE20170893 A1 PE 20170893A1
Authority
PE
Peru
Prior art keywords
alkylaryl
oxyaril
pirrol
negative allosteric
octahydro cyclopenta
Prior art date
Application number
PE2017000506A
Other languages
English (en)
Spanish (es)
Inventor
David R Anderson
Robert A Volkmann
Frank S Menniti
Original Assignee
Luc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55581945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170893(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Luc Therapeutics Inc filed Critical Luc Therapeutics Inc
Publication of PE20170893A1 publication Critical patent/PE20170893A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2017000506A 2014-09-26 2015-09-23 N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostericos negativos de nr2b PE20170893A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462056284P 2014-09-26 2014-09-26

Publications (1)

Publication Number Publication Date
PE20170893A1 true PE20170893A1 (es) 2017-07-12

Family

ID=55581945

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000506A PE20170893A1 (es) 2014-09-26 2015-09-23 N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostericos negativos de nr2b

Country Status (40)

Country Link
US (4) US10239835B2 (enExample)
EP (4) EP3197868B1 (enExample)
JP (5) JP6473227B2 (enExample)
KR (1) KR102479356B1 (enExample)
CN (1) CN106795111B (enExample)
AP (1) AP2017009832A0 (enExample)
AR (1) AR103199A1 (enExample)
AU (1) AU2015320721B2 (enExample)
BR (1) BR112017006093B1 (enExample)
CA (1) CA2962569C (enExample)
CL (1) CL2017000474A1 (enExample)
CO (1) CO2017002494A2 (enExample)
CR (1) CR20170114A (enExample)
CU (1) CU24482B1 (enExample)
CY (1) CY1123533T1 (enExample)
DK (1) DK3197868T3 (enExample)
EA (1) EA034937B1 (enExample)
EC (1) ECSP17025302A (enExample)
ES (3) ES2956546T3 (enExample)
GT (1) GT201700062A (enExample)
HR (1) HRP20200959T1 (enExample)
HU (1) HUE049698T2 (enExample)
IL (1) IL250909B (enExample)
JO (1) JO3579B1 (enExample)
LT (1) LT3197868T (enExample)
MX (1) MX374657B (enExample)
MY (1) MY182342A (enExample)
NZ (1) NZ729569A (enExample)
PE (1) PE20170893A1 (enExample)
PH (1) PH12017500513A1 (enExample)
PL (1) PL3197868T3 (enExample)
PT (1) PT3197868T (enExample)
RS (1) RS60497B1 (enExample)
SG (1) SG11201702023QA (enExample)
SI (1) SI3197868T1 (enExample)
TN (1) TN2017000076A1 (enExample)
TW (1) TWI687407B (enExample)
UY (1) UY36326A (enExample)
WO (1) WO2016049165A1 (enExample)
ZA (1) ZA201701061B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3579B1 (ar) * 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
EP3651762B1 (en) 2017-07-12 2024-07-03 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
JP7270989B2 (ja) 2017-10-20 2023-05-11 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体m4のアンタゴニスト
ES2982890T3 (es) 2017-10-31 2024-10-18 Univ Vanderbilt Antagonistas del receptor muscarínico de acetilcolina M4
CA3090130A1 (en) 2018-02-02 2019-08-08 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
WO2019173188A1 (en) 2018-03-05 2019-09-12 Arcus Biosciences, Inc. Arginase inhibitors
US12398143B2 (en) 2019-06-04 2025-08-26 Boehringer Ingelheim International Gmbh Imidazopyrazine derivatives and the use thereof as medicament
WO2020245136A1 (en) * 2019-06-04 2020-12-10 Boehringer Ingelheim International Gmbh Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders
CN111481543A (zh) * 2020-05-21 2020-08-04 苏州健雄职业技术学院 Nr2b负变构调节剂联合gaba受体调节剂在制备治疗阿尔兹海默症的药物中的用途
EP4255419A1 (en) * 2020-12-04 2023-10-11 Novartis AG Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression
CN116744922A (zh) * 2020-12-04 2023-09-12 诺华股份有限公司 Nr2b-nmda受体nam在治疗抑郁症中的剂量方案
JP2021058765A (ja) * 2021-01-19 2021-04-15 株式会社藤商事 遊技機
CN117120053A (zh) * 2021-03-26 2023-11-24 诺华股份有限公司 新的环戊二烯并[c]吡咯NR2B负变构调节剂
CN117157072A (zh) * 2021-03-26 2023-12-01 诺华股份有限公司 新型环戊基并[c]吡咯NR2B负变构调节剂
CN119654149A (zh) 2022-06-02 2025-03-18 诺华股份有限公司 用于在治疗抑郁障碍中使用的奥法地尔的皮下施用和给药方法
IL322082A (en) 2023-01-12 2025-09-01 Novartis Ag Engineered ketoreductase polypeptides
WO2025120013A1 (en) 2023-12-06 2025-06-12 Novartis Ag Compositions and methods for treating depression disorders

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532243A (en) 1992-02-14 1996-07-02 The Dupont Merck Pharmaceutical Company Antipsychotic nitrogen-containing bicyclic compounds
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
DE4341403A1 (de) 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
US5726172A (en) 1996-01-16 1998-03-10 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
AU2005219438B2 (en) 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
ATE382623T1 (de) * 2004-06-09 2008-01-15 Hoffmann La Roche Octahydropyrrolo(3,4-c)pyrrolderivate und deren verwendung als antivirale mitteln
WO2006012396A1 (en) 2004-07-22 2006-02-02 Glaxo Group Limited Antibacterial agents
HUP0401523A3 (en) 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
CA2603876A1 (en) 2005-04-19 2006-10-26 Merck & Co., Inc. N-alkyl-azacycloalkyl nmda/nr2b antagonists
EP1849772A1 (en) 2006-04-28 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
US8299113B2 (en) 2006-04-28 2012-10-30 Laboratorios Del Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
TW200845977A (en) 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
CA2703203C (en) 2007-10-22 2015-12-15 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
RU2487866C2 (ru) 2008-01-23 2013-07-20 Цзянсу Хэнсох Фармасьютикал Ко., Лтд. Производные дициклоазаалкана, способы их получения и их применение в медицине
MX2011006169A (es) 2008-12-12 2011-06-27 Univ Vanderbilt Inhibidores 3.3.0-biciclicos de giyt1 y metodos para hacer y utilizar los mismos.
FR2945534B1 (fr) 2009-05-12 2012-11-16 Sanofi Aventis DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2945533B1 (fr) * 2009-05-12 2011-05-27 Sanofi Aventis Derives de cyclopenta°c!pyrrolyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
ES2534516T3 (es) 2010-01-07 2015-04-23 E.I. Du Pont De Nemours And Company Compuestos heterocíclicos fungicidas
WO2011149993A2 (en) 2010-05-25 2011-12-01 Abbott Laboratories SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS
CN102432598A (zh) * 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
FR2974729B1 (fr) 2011-05-02 2013-04-19 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
US8501768B2 (en) 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
JP6075736B2 (ja) 2011-12-21 2017-02-08 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. ピロール−6員ヘテロアリール環誘導体、その合成法およびその医薬用途
PL2900669T3 (pl) * 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US9418332B2 (en) 2013-08-16 2016-08-16 Qualcomm Incorporated Post ghost plasticity
US9540324B2 (en) 2013-09-26 2017-01-10 Luc Therapeutics, Inc. Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول

Also Published As

Publication number Publication date
PL3197868T3 (pl) 2020-11-02
EP3683207A1 (en) 2020-07-22
BR112017006093A2 (pt) 2017-12-19
HRP20200959T1 (hr) 2020-10-02
CU20170037A7 (es) 2017-08-08
KR102479356B1 (ko) 2022-12-19
ES2911004T3 (es) 2022-05-17
US20190152912A1 (en) 2019-05-23
EA201790713A1 (ru) 2017-07-31
IL250909B (en) 2019-06-30
JP2019077713A (ja) 2019-05-23
AU2015320721B2 (en) 2020-01-30
EP4282412A3 (en) 2024-01-17
NZ729569A (en) 2019-06-28
JP2017528502A (ja) 2017-09-28
WO2016049165A1 (en) 2016-03-31
ES2791327T3 (es) 2020-11-03
HUE049698T2 (hu) 2020-10-28
GT201700062A (es) 2019-09-30
US10239835B2 (en) 2019-03-26
ES2956546T3 (es) 2023-12-22
PT3197868T (pt) 2020-05-21
SG11201702023QA (en) 2017-04-27
MY182342A (en) 2021-01-20
CA2962569A1 (en) 2016-03-31
EP3974420B1 (en) 2023-08-16
EP3197868A4 (en) 2018-04-25
PH12017500513A1 (en) 2017-08-07
RS60497B1 (sr) 2020-08-31
US20180111902A1 (en) 2018-04-26
US20200369610A1 (en) 2020-11-26
CO2017002494A2 (es) 2017-08-31
EP3197868A1 (en) 2017-08-02
KR20170063599A (ko) 2017-06-08
EA034937B1 (ru) 2020-04-08
EP3197868B1 (en) 2020-04-15
ZA201701061B (en) 2019-07-31
MX374657B (es) 2025-03-06
AP2017009832A0 (en) 2017-03-31
JO3579B1 (ar) 2020-07-05
AR103199A1 (es) 2017-04-26
ECSP17025302A (es) 2018-11-30
JP2025060835A (ja) 2025-04-10
US20220274925A1 (en) 2022-09-01
EP4282412A2 (en) 2023-11-29
IL250909A0 (en) 2017-04-30
CY1123533T1 (el) 2022-03-24
MX2017003940A (es) 2018-03-01
CU24482B1 (es) 2020-03-04
JP2021006554A (ja) 2021-01-21
TN2017000076A1 (en) 2018-07-04
US12145909B2 (en) 2024-11-19
EP3974420A1 (en) 2022-03-30
BR112017006093B1 (pt) 2023-03-21
UY36326A (es) 2016-04-29
AU2015320721A1 (en) 2017-03-30
EP3683207B1 (en) 2021-12-29
JP6473227B2 (ja) 2019-02-20
CN106795111B (zh) 2020-04-07
SI3197868T1 (sl) 2020-10-30
JP7612722B2 (ja) 2025-01-14
CA2962569C (en) 2023-09-19
US10781174B2 (en) 2020-09-22
JP6772307B2 (ja) 2020-10-21
CR20170114A (es) 2017-08-21
CL2017000474A1 (es) 2017-08-18
CN106795111A (zh) 2017-05-31
TW201625528A (zh) 2016-07-16
TWI687407B (zh) 2020-03-11
DK3197868T3 (da) 2020-06-22
JP7216060B2 (ja) 2023-01-31
JP2023052515A (ja) 2023-04-11
LT3197868T (lt) 2020-09-10

Similar Documents

Publication Publication Date Title
CY1125539T1 (el) Παραγωγα αζετιδινης ως ρυθμιστες του υποδοχεα χημειοκινης και χρηση αυτων
PE20171329A1 (es) Agentes inmunorreguladores
PH12019502003A1 (en) Cyclic sulfamide compounds and methods of using same
PE20200696A1 (es) Moduladores de moleculas pequenas de sting humana
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CL2019002590A1 (es) Compuestos de dinucleótidos cíclicos modificados.
MX2021015102A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
PE20201448A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
PE20141974A1 (es) Compuestos de heterociclilo
PE20171623A1 (es) Agentes inmunomoduladores
PE20181269A1 (es) Agonistas del receptor de apelina y metodos de uso
PE20160875A1 (es) Compuestos de biaril-amida como inhibidores de cinasa
EA201170349A1 (ru) Модуляторы mif
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
PE20150352A1 (es) Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona
MA40219B1 (fr) Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
JOP20200022A1 (ar) مركبات حلقية لولبية وطرق تصنيعها واستخدامها
EA201592082A1 (ru) 3,4-дигидроизохинолин-2(1h)-ильные соединения
JO3579B1 (ar) مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
EA201491610A1 (ru) Модуляторы x рецепторов печени
EA202091120A2 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
EA201692550A1 (ru) Соединения, содержащие систему 1,1',2,5'-тетрагидроспиро[индол-3,2'-пиррол]-2,5'-диона в качестве ингибиторов белок-белкового взаимодействия p53-mdm2
EA201491609A1 (ru) Модуляторы x рецепторов печени